Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)


29 Sep 2019


Poster Display session 2


Tumour Site

Hepatobiliary Cancers


Sirish Dharmapuri


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


S. Dharmapuri1, U. Özbek2, J. Lin2, M. Schwartz3, A. Branch4, C. Ang1

Author affiliations

  • 1 Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
  • 2 Department Of Population Health Science And Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
  • 3 Recanati/miller Transplant Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US
  • 4 Hepatology, Icahn School of Medicine at Mount Sinai, 10029 - New York/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1602


Currently there are no recognized or validated biomarkers to identify HCC patients(pts) likely to benefit from N. Several studies have established the inverse relationship between inflammation-based scores such as NLR, PLR and survival in other solid tumours treated with immunotherapy. We evaluated the relationship between NLR and PLR and survival outcomes in HCC pts treated with N at Mount Sinai Hospital.


One hundred and four HCC pts treated between June 2016 and July 2018 were identified. NLR=Absolute neutrophil count/ Absolute lymphocyte count (ALC) and was calculated pretreatment and at 6-8 weeks after 3 doses (Posttreatment) of N. PLR=Platelet count/ALC. Kaplan-Meier analysis and the log-rank test were used to calculate and compare Overall and Progression free survival (OS, PFS) between NLR <5 vs ≥ 5 and among PLR tertiles.


Median age was 66 (29-89) years. Median treatment duration was 26 (2-149) weeks. Child Pugh score (CPS, N = 96) was A in 64 (66%) and B in 32 (33%) pts. Barcelona Clinic Liver Cancer (BCLC) stage was B in 21 (20%) and C in 83 (80%) pts. Median follow-up time was 17 months (95% CI (15.7, 20.7). NLR was <5 in 64 (62%) pts pretreatment and 59 (60%) pts post treatment. NLR<5 was associated with improved OS compared to NLR≥5 both pretreatment (23 Vs 10 months, P = 0.0037) and post treatment (35 Vs 9 months, P < 0.0001). Survival also differed significantly among PLR tertiles (Table), with median OS for the lowest post treatment tertile not yet reached. Median PFS differed significantly between pre (16 Vs 5 months, P = 0.0217) and post (35 Vs 5 months, P = 0.0002) treatment NLR. PLR was not significantly associated with PFS. In a multivariable model, port treatment PLR and NLR were significantly associated with OS.Table:


Pretreatment PLR groupN(%)OS (months)
< 11936(36)35P = 0.0495
 > = 119 & < 22432(31)10
 > = 22433(33)15
Post treatment PLR group
< 12635(35)Not ReachedP = 0.0126
 > = 126 & < 22931(31)19
 > = 22933(33)10


This study suggests that lower NLR and PLR levels may predict better survival outcomes in HCC patients treated with N. The potential role of NLR and PLR as early predictors of immunotherapy outcomes in HCC pts warrants further evaluation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Mount Sinai Hospital.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.